First Human Trial of 'Reverse-Aging' Drug Begins with Cellular Reprogramming

Life Biosciences has launched the first human clinical trial of a cellular reprogramming therapy, dosing patients with its experimental drug ER-100. The treatment aims to induce damaged eye cells to act like younger, healthier cells, a concept often described as 'reverse aging.'

This development brings cellular reprogramming—a technique previously limited to lab settings—into the clinical stage for the first time. The trial focuses on eye health, but the underlying technology could have broader implications for age-related diseases.